Anti-Human CTLA-4 (Ipilimumab) – Fc Muted™
Pricing & Details
FC Effector Activity
≥ 2.0 mg/ml
<0.5 EU/mg as determined by the LAL method
>95% by SDS-PAGE and HPLC
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
See directions on lot specific datasheets, as information may periodically change.
Applications and Recommended Usage ?
(Quality Tested by Leinco)
FC The suggested concentration for Ipilimumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications.
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for research use only.
CTLA4 is constitutively expressed in regulatory T cells.
Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body’s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body’s own immune response against cancer cells.”2 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.1 This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.
NCBI Gene Bank ID
References & Citations
1. Wolchok, JD. et al. (2013) N Engl J Med 369(2):122-33.
2. Soo, RA. et al. (2017) Lancet Oncol. 18(12):e731-e741.
3. Lipson, EJ. and Drake, CG. (2011) Clin Cancer Res 17(22):6958-62.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.